Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584497 | 1.00 | BACE1 (0.56) | BACE1PPARGPPARAKDM4EMEN1 | |
| SCHEMBL6539436 | 0.85 | BACE1 (0.45) | BACE1MEN1KMT2AALDH1A1ITGA4 | |
| SCHEMBL12835896 | 0.82 | BACE1 (0.48) | BACE1PPARGPPARAKDM4EMEN1 | |
| SCHEMBL6539195 | 0.79 | BACE1 (0.54) | BACE1ADRB1ADRB3 | |
| SCHEMBL6538940 | 0.79 | BACE1 (0.54) | BACE1ADRB1ADRB3 | |
| SCHEMBL6538935 | 0.79 | BACE1 (0.54) | BACE1ADRB1ADRB3 | |
| SCHEMBL4973190 | 0.78 | BACE1 (0.48) | BACE1MEN1KMT2AALDH1A1ITGA4 | |
| SCHEMBL27459831 | 0.78 | BACE1 (0.48) | BACE1MEN1KMT2AALDH1A1ITGA4 | |
| SCHEMBL11214244 | 0.76 | F2R (0.45) | BACE1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10190452 | 0.75 | BACE1 (0.43) | BACE1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417060-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2008-08-26 | — | — | US | disclosed |
| EP-1697301-A2 | AMINOALCOHOL DERIVATIVES | Astellas Pharma Inc. (JP) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005061433-A2 | AMINOALCOHOL DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2005-07-07 | — | — | WO | disclosed |
| US-20050137236-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137236-A1 | Aminoalcohol derivatives | GPR39, PRMT9, CHRM2 | BACE1 3089/4885PPARG 658/4885PPARA 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.